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Innate immune system activation 
in zebrafish and cellular models of 
Diamond Blackfan Anemia
Nadia Danilova1, Mark Wilkes2, Elena Bibikova2, Min-Young Youn2, Kathleen M. Sakamoto2 & 
Shuo Lin1
Deficiency of ribosomal proteins (RPs) leads to Diamond Blackfan Anemia (DBA) associated with 
anemia, congenital defects, and cancer. While p53 activation is responsible for many features of 
DBA, the role of immune system is less defined. The Innate immune system can be activated by 
endogenous nucleic acids from non-processed pre-rRNAs, DNA damage, and apoptosis that occurs in 
DBA. Recognition by toll like receptors (TLRs) and Mda5-like sensors induces interferons (IFNs) and 
inflammation. Dying cells can also activate complement system. Therefore we analyzed the status of 
these pathways in RP-deficient zebrafish and found upregulation of interferon, inflammatory cytokines 
and mediators, and complement. We also found upregulation of receptors signaling to IFNs including 
Mda5, Tlr3, and Tlr9. TGFb family member activin was also upregulated in RP-deficient zebrafish and in 
RPS19-deficient human cells, which include a lymphoid cell line from a DBA patient, and fetal liver cells 
and K562 cells transduced with RPS19 shRNA. Treatment of RP-deficient zebrafish with a TLR3 inhibitor 
decreased IFNs activation, acute phase response, and apoptosis and improved their hematopoiesis and 
morphology. Inhibitors of complement and activin also had beneficial effects. Our studies suggest that 
innate immune system contributes to the phenotype of RPS19-deficient zebrafish and human cells.
Diamond-Blackfan Anemia (DBA) is a bone marrow failure syndrome, which is also characterized by congenital 
malformations and cancer1,2. DBA is caused by mutations in ribosomal proteins (RPs), most often in RPS19, while 
mutations in several other RPs are found at lower frequencies3,4. The RPs affected in DBA are required for pro-
cessing of pre-rRNA; their deficiency leads to the accumulation of non-processed pre-rRNA and the impairment 
of ribosome biogenesis5–8.
p53 activation is a common response to RP deficiency9–13. Inhibition of p53 decreases hematopoietic and 
developmental defects in animal models of DBA suggesting that p53 upregulation is involved in the pathogenesis 
of DBA. Activation of p53 independent signaling pathways in DBA has also been reported12,14 however their role 
and interaction with the p53 network is not well defined.
The role of immune system in DBA is not clear. Lymphoid cells have been suggested to play a role in DBA 
pathophysiology but further studies failed to demonstrate significant impact of these cells15. Recent analysis of 
the immune status of patients with various bone marrow failure conditions performed by Giri et al.16 show that 
most DBA patients have normal number and function of immune cells. However some data suggest upregulation 
of interferon (IFN) signaling and inflammation in DBA. The analysis of erythrocyte cytoplasmic proteome from 
DBA patients cells show increased presence of IFN targets and immunoproteasome components17. Increased 
expression of genes associated with IFN and TNF pathways has been noted in hematopoietic progenitors18. 
Importantly, interferon regulatory factor 9 (IRF9) essential for type I IFN signaling was 2.84 fold upregulated in 
multipotential hematopoietic progenitors. Altered expression of genes associated with inflammation, NFkB and 
TNF signaling have been found in fibroblasts from DBA patients such as ~14 fold increase in TNF alpha induced 
protein 3 (TNFAIP3)19. Monocytes from DBA patients are oversensitive to LPS stimulation and produce higher 
levels of cytokines such as TNF, IL6, and others in response to low dose of LPS20. The authors concluded that these 
patients might have “a chronic subclinical inflammatory micro-environment in the bone marrow”. TNF upregu-
lation has also been noted in human hematopoietic progenitors with RPS19 knockdown21.
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On the other hand, some patients with ribosomopathies demonstrate features of immunodeficiency22,23. A 
decreased proliferation rate and translational capacity of lymphoid cells from DBA patients has been reported24. 
Therefore, it is important to understand the precise contribution of not only adaptive but also innate immunity 
in DBA.
One of the major arms of innate immunity is complement system, a cascade of enzymes and other factors 
that promotes phagocytosis and inflammation and induces lysis of pathogens and compromised cells25,26. The 
central event in this cascade is a cleavage of complement factor 3 with production of a reactive C3b fragment that 
can covalently bind to surfaces of microbes and cells. Over activation of complement is associated with several 
hematologic disorders such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, cold 
agglutinin disease and others27. The role of complement in DBA has not been studied.
Innate immunity includes autonomous immune mechanisms that are active not only in immune cells but 
also practically in all nucleated cells, especially in those of epithelial origin28,29. Several hundreds of proteins 
are involved in autonomous immune protection. They include receptors that recognize molecules specific for 
pathogens, called pattern recognition receptors (PRRs) and various effectors that restrict the spread of pathogen 
or induce cell death. In addition, infected cells produce cytokines such as interferons that activate autonomous 
immune mechanisms in neighboring cells. Interferons regulate a large fraction of autonomous immune genes30. 
IFN type I and III are induced when PRRs bind products from pathogens activating IFN regulatory factors (IRF) 
3, 5, and 7, c-Jun, and NFkB. This leads to the formation of a signaling complex that contains STAT1 and 2 and 
interferon regulatory factor 9 (IRF9). This complex drives the expression of IFN-stimulated genes (ISGs).
Another innate immune mechanism is inflammation, which is associated with the recruitment of immune 
cells to the site of infection or injury and induction of fever. It translates autonomous response at the cellular level 
to the response on the level of organism. Many cells respond to infection, stress and other homeostasis-altering 
processes by assembly of inflammasomes31. These protein complexes cleave precursors of cytokines such as IL-1 
and IL-18 leading to their secretion and induction of inflammation.
Innate immunity can sense not only features of pathogens but also abnormal or misplaced self-molecules32. 
Several classes of immune receptors can be activated by endogenous ligands. Mda5 (melanoma differentia-
tion associated protein 5), an RNA helicase from Rig1-like receptor (RLR) family, recognizes dsRNA. dsRNA 
is not restricted to viruses; 3-UTRs of mRNAs and some non-coding RNAs such as rRNA often contain 
self-complementary regions that can form double-stranded structures33,34. Mda5 also recognizes mRNAs that 
lack 2-O-methylation at their 5 caps. Human studies show that MDA5 overactivation contributes to autoimmune 
diseases such as systemic lupus erythematosus and diabetes34. Toll-like receptor 3 (TLR3) recognizes dsRNA and 
other RNAs35–37. DNA sensors such as TLR9 can recognize DNA from apoptotic cells and mitochondrial DNA37. 
DNA damage is associated with the production of DNA fragments that are used in DNA repair; some of these 
fragments can leak into cytoplasm and activate DNA sensors38,39. Alternatively, RNA Pol III can convert them 
into dsRNA, which then is recognized by dsRNA sensors such as Mda540. Abnormal composition of membranes 
may affect the interaction of cells with the complement system, an intrinsically unstable cascade of enzymes that 
can induce cell lysis and inflammation32. Activation of PRRs can lead to upregulation of interferons, NFkB, and 
inflammation. Complement system can be activated by components of apoptotic and necrotic cells41.
RP-deficient cells have many alterations that can activate innate immune response: they accumulate 
non-processed pre-rRNA4–8, have altered membranes42, have increased DNA damage43, and are prone to apopto-
sis44. We therefore hypothesized that DBA may be associated with increased interferon production, inflammation, 
and activated complement. The advantage of using zebrafish to study the role of innate immunity in DBA is the 
absence of a functional adaptive immune system during the first several days of zebrafish development. At this 
stage, the autonomous immune mechanisms, innate immune cells, and complement provide the immune protec-
tion. Therefore, contribution of these immune mechanisms to the RP-deficient phenotype can be studied without 
interference from T and B cells. We used a combination of two different models of RP deficiency, a genetic mutant 
for rpl11 gene from a large ribosomal subunit and RP deficiency created by morpholino for rps19 gene from a 
small ribosomal subunit. Using two models from different subunits and created by different mechanisms let us to 
discern general features of the innate immune system response to RP deficiency.
We report in this paper that interferon network was upregulated in RP-deficient zebrafish model of DBA. We 
found increased expression of interferon regulators and interferon-stimulated genes (ISGs) both in zebrafish 
Rpl11 mutant and Rps19 morphants. Genes encoding for Mda5, Tlr3, and Tlr9 receptors that signal to IFNs were 
upregulated. We also found upregulation of inflammatory pathways including increased expression of genes for 
Tnf and IL-6 (interleukin 6). Changes in expression of activin/inhibin subunits in Rps19-deficient zebrafish and 
RPS19-deficient human primary cells and cell lines pointed to activin upregulation. Complement system was 
also upregulated in RP-deficient zebrafish. Inhibitors of TLR3, activin, and complement improved condition of 
Rps19-deficient zebrafish. Our data suggest that the innate immune system activation could contribute to the 
pathophysiology of DBA.
Results
Zebrafish models of DBA. To study the innate immune responses in RP-deficient zebrafish, we used rps19 
gene from a small ribosomal subunit and rpl11 gene from a large ribosomal subunit. Rpl11 mutant was generated 
in Nancy Hopkins lab45 and characterized in our lab12. Previously we created an Rps19-deficient fish using a 
morpholino, which was highly specific as was confirmed by using an alternative translational morpholino, rescue 
of morphant phenotype by rps19 mRNA, and use of scrambled morpholino that had no effect on embryos at any 
dose studied up to 13 ng per embryo9. Although Rps19 mutant is also available, the morpholino model is prefera-
ble to genetic mutants in certain settings, such as when evaluating the effects of drug treatment. Rpl11 and Rps19 
mutants are viable only as heterozygotes; correspondingly, mutants comprise only 25% of their progeny and to 
evaluate the effect of drug treatment, each embryo needs to be genotyped. In addition, morpholino-injected 
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embryos can be analyzed at any time point during development while mutants can be reliably separated from 
their wild-type siblings only at 48 hpf. We also used this morpholino to create Rps19 deficiency on p53 negative 
background in p53 zebrafish mutant.
Interferon network is upregulated in RP-deficient zebrafish. We examined expression of the 
components of the interferon network in RP-deficient zebrafish. Interferon regulatory factors Irf3 and Irf7 are 
key controllers of type I IFNs. They regulate the transcription of IFN-alpha and beta as well as transcription of 
IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element in their promoters46,47. We 
found increased expression of both irf3 and irf7 in Rpl11 mutant and Rps19 morphants (Fig. 1A,B). INFs signal 
through STAT proteins to activate the transcription of interferon stimulated genes (ISGs). In RP-deficient zebraf-
ish, stat1b and stat3 were upregulated (Fig. 1A,B). IFN signaling induces several IFN inhibitors including Socs3a 
and b (suppressors of cytokine signaling 3) members of the STAT-induced STAT inhibitor family. These genes 
were also upregulated in both RP-deficient models (Fig. 1A,B).
Upregulation of ISG genes is another indicator of interferon system activation. The interferon-induced gene, 
isg15 (ubiquiting-like modifier 15) is a sensitive indicator of interferon activation. The product of the isg15 gene 
is an ubiquitin-like protein that is conjugated to intracellular target proteins upon activation by interferons48. 
isg15 was the second-most upregulated gene in Rpl11 mutants according to microarray data verified by qPCR 
(Fig. 1A). It was also upregulated in Rps19-deficient zebrafish (Fig. 1B). A number of other ISG genes have been 
upregulated. They include a gene encoding Gbp2 (guanylate binding protein 2, interferon-inducible), which was 
2.5 fold upregulated in Rpl11 mutant microarray and 2.8 fold upregulated in Rps19 morphants (data not shown). 
Gbp2 hydrolyzes GTP to GMP, promotes oxidative killing, and delivers antimicrobial peptides to autophagolys-
osomes49. An ISG gene encoding another GTP-metabolizing protein, MxA, was 2.2 fold upregulated in Rps19 
morphants (data not shown). Mknk2b kinase that mediates suppressive effect of IFN-gamma on hematopoiesis 
was 2.5-fold upregulated in Rpl11 microarray. Another 3-fold upregulated ISG in Rpl11 mutant is gtpbp1 (GTP 
binding protein 1) that promotes degradation of RNA species in exosomes. Therefore various components of 
interferon signaling network were upregulated in Rpl11 mutant and in Rps19 morphants.
There is cross talk between p53 and the interferon network. P53 has an IFN-stimulated response element 
in its promoter and therefore is induced by interferons50. In turn, p53 enhances interferon responses51. For that 
reason we examined the effect of p53 on the expression of the key IFN regulator ifr7. This gene was upregulated 
in p53-/- zebrafish mutant (Fig. 1C), which suggests that IFN network upregulation in RP-deficient zebrafish is 
at least partially p53 independent. The irf7 expression decreases when development progresses, a pattern simi-
lar to tp53 expression during development, which may be associated with decreasing stemness and increasing 
differentiation52.
Expression of immune receptors signaling to IFN is altered in zebrafish models of DBA. In 
RP-deficient cells, interferons can be induced by endogenous ligands such as DNA and RNA from apoptotic 
bodies, non-processed faulty rRNA, and DNA fragments leaking to cytoplasm during DNA repair. RNA Pol III 
can convert them into RNA. Expression of several subunits of RNA Pol III have been upregulated in a microarray 
from Rpl11 mutants including polr3f, 2.3 fold, polr3e, 2.2 fold, polr3k, 2.1 fold, and a subunit of RNA Pol III tran-
scription initiation factor brf1, 12 fold as has been confirmed by RT-qPCR. Therefore upregulated RNA Pol III 
could convert most DNA fragment originated during DNA repair into RNA, which can contain regions forming 
dsRNA.
One of the major cytosolic sensors of dsRNA is an innate immune receptor Mda5 encoded by ifih1 (interferon 
induced with helicase C domain 1) gene32. Mda5 signals through interferon regulatory factors Irf3 and Irf7 to 
Figure 1. Interferon signaling was upregulated in RP-deficient zebrafish. (A) Interferon regulators irf3 and irf7 
were upregulated in Rpl11 mutants along with signal transducers stat3 and stat1b and interferon induced gene 
isg15, 48 hpf (hours post fertilization), RT-qPCR. Fold change in expression was calculated relative to wild-type 
embryos. RNA in this and other experiments was derived from a pool of at least 30 embryos. (B) The same set 
of genes was upregulated in embryos injected with Rps19 morpholino, 28 hpf, RT-qPCR. Injection of rps19 
control mismatch morpholino did not upregulate genes from the interferon network. (C) irf7 was upregulated 
in p53−/− mutant injected with Rps19 morpholino, RT-qPCR. (St1b, stat1b; st3, stat3; s3a, socs3a; s3b, socs3b. 
Bars represent the mean of three replicates ± sd. Asterisk indicates significant difference in comparison to 
controls, p < 0.05.
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induce type I interferons. ifih1 that encodes Mda5, was upregulated both in Rpl11 mutants and in Rps19 mor-
phants (Fig. 2A,B).
Toll-like receptor 3 is endosomal sensor of dsRNAs and other RNAs. RNA ligands can be delivered to endo-
somes through autophagy that is increased in DBA cells53. tlr3 was upregulated both in Rpl11 mutants and in 
Rps19 morphants (Fig. 2A,B). Besides tlr3, we found upregulation of genes encoding toll-like receptor Tlr9, 
which recognizes DNA and Tlr1, which recognizes lipoproteins (Fig. 2B). No endogenous ligands have been 
identified for Tlr1 but literature suggests their existence since polymorphism in human TLR1 affects severity 
of allergy54. All TLRs, except for Tlr3, signal through MyD88 to induce NFkB and Irf7, while Tlr3 also induces 
Irf3-dependent transcription55.
Interestingly, the expression of genes encoding Tlr5α and Tlr5β, which recognize bacterial flagellin and do 
not have endogenous ligands was decreased (Fig. 2B). Furthermore Rpl11 mutant microarray data shows 4.4 fold 
decrease in level of defensin beta, 1.5 fold decrease in lysozymes, and 1.7 fold decrease in amyloid beta precursor. 
This suggests that at least some innate immune responses can be weakened in an RP-deficient organism.
It was shown that TLRs, especially TLR3, could be upregulated by p53 in response to DNA stressors56,57. To 
evaluate p53 contribution to tlr3 upregulation we injected tp53-/- mutants with Rps19-specific morpholino and 
measured tlr3 expression. tlr3 was upregulated in a p53-negative background (Fig. 1C). This finding indicates 
that tlr3 upregulation in RP-deficient zebrafish is at least partially p53-independent. Interestingly, tlr3 expression 
decreases during development, a pattern also seen with tp53 and irf7.
Inflammatory pathways are upregulated in RP-deficient zebrafish. Upregulation of innate 
immune receptors may lead to the activation of inflammatory pathways. We found upregulation of several 
pro-inflammatory cytokines and inflammatory mediators in RP-deficient zebrafish embryos (Fig. 3A,B). This 
includes cytokines interleukin 6 (il6) and tumor necrosis factor (tnf) along with its receptor tnfrsf1a, matrix met-
allopeptidases 9 and 13, fibrinogen, and ptgs2 (prostaglandin-endoperoxide synthase-2), encoding for the Cox-2 
enzyme. Cox-2 catalyzes the rate-limiting step of prostaglandin biosynthesis and is the target of non-steroidal 
anti-inflammatory drugs like aspirin.
TGFβ signaling is altered in Rps19-deficient zebrafish and in RPS19-deficient human 
cells. Toll-like receptor agonists can stimulate release from macrophages of activin A, a pro-inflammatory 
cytokine from the TGFβ family58. We therefore examined expression of activin subunits in RP-deficient zebrafish. 
Activin is counterbalanced by inhibin, a factor with an opposite activity. Both activin and inhibin are dimers. 
Activin is composed of two beta subunits that can be identical or different. Inhibin shares beta subunits with the 
activin, but the other subunit, alpha, is unique to inhibin. Therefore, changes in expression of the alpha subunit 
would affect the amount of beta subunits available for inhibin and, consequently, affect the activin/inhibin ratio. 
In Rps19 deficient zebrafish, expression of a subunit InhAa, unique to inhibin, was decreased, while expression of 
subunits inhBa and inhBb common for both inhibin and activin, was unchanged (Fig. 4A). It means the activin/
inhibin equilibrium was shifted to activin in RP-deficient zebrafish. Another indicator of activin overproduction 
was upregulation of follistatin, a protein that binds and inhibits activin (Fig. 4B). We also found upregulation of 
smad7, an inhibitory SMAD that suppresses TGFβ signaling.
Inhibin alpha (INHA) was also among downregulated genes in cellular models of DBA. We transduced human 
human CD34+ fetal liver cells and K562 cells (tp53-/-) with lentiviral vectors expressing short hairpin RNA 
(shRNA) against RPS1943,59. In this system, we achieved ~50% reduction in RPS19 protein level34,50. In K562 cells 
with RPS19 knockdown, microarray analysis revealed INHA among the most downregulated genes (Fig. 4C). 
Since no changes in expression of beta subunits INHBA and INHBB have been detected by microarray, these data 
Figure 2. Expression of innate immune receptors was altered in RP-deficient zebrafish. (A) ifih1 and tlr3 
that recognize RNAs were upregulated in Rpl11 mutants. 48 hpf. RT-qPCR. Shown fold changes against wild 
type siblings (B) ifih1 and tlr3 were also upregulated in embryos injected with Rps19-specific morpholino 
in comparison to wild-type control. tlr9 that recognizes DNA and tlr1 that recognizes lipoproteins were also 
upregulated. Expression of tlr5a/b that recognize bacterial flagellin was decreased. 28 hpf, RT-qPCR,. (C) tlr3 
was upregulated in tp53−/− mutants injected with Rps19 specific morpholino. Fold change was calculated 
relative to tlr3 expression at 0 hpf. RT-qPCR. The bars represent the mean of three replicates ± sd. Asterisk 
indicates significant difference in comparison to controls, p < 0.05.
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point to activin overproduction in these cells. INHA expression was also decreased in RPS19-deficient human 
fetal liver (Fig. 4D), and in lymphoid cell lines from a DBA patient with an RPS19 mutation (Fig. 4E).
These data suggest TGFβ family member activin with proinflammatory properties was over-produced in 
zebrafish DBA models and in human cells deficient in RPS19. Activin overproduction was detected both in a wild 
type and a p53-negative background. This suggests that the increase in activin production in DBA models does 
not depend on p53.
Complement system is upregulated in RP-deficient zebrafish. Complement system can be activated 
by different mechanisms even in absence of infection. Spontaneous C3 hydrolysis and binding of C3 convertase 
enzyme to cells initiate the alternative pathway of complement26. Normally, it is limited by activity of factor H 
and complement regulatory proteins acting on cell surface to clear complement complexes. In pathological con-
ditions the balance between complement activation and inhibition is broken and C3 convertase can recruit more 
complement proteins onto the cell surface leading to the formation of the membrane attack complex, cell damage, 
activation of phagocytosis, and inflammation.
In Rpl11 microarray confirmed by RT-qPCR we found significant upregulation of complement component 
6 (Fig. 5A). C6 is a part of the membrane attack complex. C3-S and C3-H1 isoforms of complement component 
3 and complement factor B (cfb) from the alternative complement pathway were also somewhat upregulated in 
Rpl11 mutants (Fig. 5A). In Rs19-deficient zebrafish, complement component C6 was also upregulated along with 
an increase in the expression of factor B (Fig. 5B). On tp53-/- background upregulation was smaller (Fig. 5C) sug-
gesting p53 activation contributes to complement activation. While complement components were upregulated, 
expression of complement inhibitor factor H was decreased (Fig. 5D). RNA-seq of Rps19-deficient zebrafish also 
suggested upregulation of c6 complement component and downregulation of inhibitory factor H60.
Application of inhibitors of TLR3 receptor, activin receptor, and complement improved the 
condition of RP-deficient zebrafish. Our data suggested that upregulation of Mda5 and some TLRs leads 
to activation of interferons, inflammation, activin, and complement, which might contribute to the RP-deficient 
phenotype. We therefore examined effects of inhibitors of these pathways on RP-deficient zebrafish. We injected 
zebrafish embryos with Rps19-specific morpholino and treated them with TLR3 receptor inhibitor, compound 
SB431542 that inhibits activin receptor, or compound SB290157 that acts as a competitive antagonist of anaphy-
loxin C3a receptor. Application of TLR3 inhibitor resulted in downregulation of interferon mediators irf7 and 
stat1b, suggesting decrease of interferon system activation (Fig. 6A). Expression of pro-inflammatory markers 
il6 and ptgs2/sox2 was also decreased after treatment as well as expression of acute-phase response gene fos. We 
also observed downregulation of p21 responsible for cell cycle arrest and a pro-apoptotic gene bax. As a result, 
we observed partial rescue of hematopoiesis (Fig. 6B) and morphology (Fig. 6C) in Rps19-deficient embryos. 
Inhibitors of activin and complement also improved hematopoiesis and morphology of Rps19-deficient embryos.
Discussion
In RP-deficient zebrafish, we found upregulation of interferons, inflammation (TNF, il6), activin, and comple-
ment. Many changes in RPs-deficient cells may contribute to the activation of these immune mechanisms. They 
include accumulation of defective pre-rRNAs, DNA damage, increased ROS, increased apoptosis, alterations in 
composition of membranes and extracellular matrix and metabolic defects among major causes. RNA and RNA 
Figure 3. Pro-inflammatory genes and inflammatory mediators were upregulated in RP-deficient zebrafish. 
(A) In rpl11 mutant, expression of genes for cytokines Il6 and Tnf was increased along with upregulation of Tnf 
receptor and matrix metallopeptidases 9 and 13. Fold change in expression was calculated relative to wild-type 
siblings. 48hpf, RT-qPCR. (B) In rps19 morphants, il6 and tnf were also upregulated along with mmp9, Cox2 
enzyme encoding ptgs2, and fibrinogen. 24hpf, RT-qPCR. Fold change in expression was calculated relative to 
wild-type embryos. Bars represent the mean of three replicates ± sd. tnfr, tnfrsf1a, fib, fibrinogen.
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Figure 4. Expression of activin/inhibin was altered in RP-deficient zebrafish and human cells. (A) inhA, 
encoding a subunit unique to inhibin, was downregulated in Rps19-deficient zebrafish embryos while 
expression of genes for subunits common to both inhibin and activin was not changed, 40 hpf, RT-qPCR. (B) 
Follistatin, which is an activin inhibitor, was upregulated in Rps19-deficient zebrafish along with upregulation 
of inhibitory Smad7, 40 hpf, RT-qPCR. (C) K562 cells transduced with anti-RPS19 shRNA showed decreased 
expression of RPS19 and INHA subunit, SCR, scrambled shRNA control, RT-qPCR. (D) Inhibin alpha was also 
downregulated in human fetal liver cells deficient in RPS19, SCR, scrambled shRNA control, RT-qPCR. (E) 
Inhibin alpha was downregulated in a lymphoid cell line derived from a DBA patient with a mutation in the 
RPS19 gene, RT-qPCR. Bars represent the mean of three replicates ± sd. Asterisk indicates significant difference 
in comparison to controls, p < 0.05.
Figure 5. Complement system was upregulated in RP-deficient zebrafish. (A) Complement components c6, 
c3-S, c3-H1, and cfb were upregulated in Rpl11 mutant zebrafish embryos, 48 hpf, RT-qPCR. (B) Complement 
components c6 and cfb were upregulated in Rps19-deficient zebrafish. 24 hpf, RT-qPCR (C) On tp53-/- 
background, c6 upregulation was much smaller, 24 hpf, RT-qPCR. (D) Inhibitor of complement factor H was 
downregulated in Rps19-deficient zebrafish embryos, 24 hpf, RT-qPCR. Bars represent the mean of three 
replicates ± sd. Asterisk indicates significant difference in comparison to controls, p < 0.05.
www.nature.com/scientificreports/
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from apoptotic bodies or from autophagosomes can get into endosomes where they are recognized correspond-
ingly by Tlr3 and Tlr9 (Fig. 7). Both these receptors have been upregulated in RP-deficient zebrafish.
We also found upregulation of cytosolic receptor Mda5 that recognizes mostly dsRNA. Upregulation of this 
receptor can be related to DNA damage we previously found in DBA models43. Induction of interferon by DNA 
damage caused by radiotherapy and chemotherapy drugs is well known and the mechanism of IFN induction was 
traced to DNA fragments that are generated during DNA double strand break repair38. Some of them can migrate 
to the cytosol where they are recognized by DNA sensors or are converted into dsRNA by RNA PolIII and rec-
ognized by RNA sensors such as Rig1 and Mda540. To prevent immune activation, DNA fragments are destroyed 
by 3′–5′ exonuclease Trex1 located on the outer side of the nuclear membrane. Deficiency of this enzyme as well 
as malfunction or insufficient activity of DNA repair proteins can cause accumulation of DNA fragments in the 
cytoplasm and stimulate NF-kB and IFN pathways38,39. In addition, delayed processing of nascent pre-rRNA 
could interfere with transcription and increase the production of DNA-RNA hybrids or their delayed removal, 
which would result in activation of innate immune sensors and IFN induction61.
Activation of the complement system in RP-deficient zebrafish may be caused by accumulation of apoptotic 
cells41 and by the alterations in composition of membranes that have been reported in DBA42. Our data suggest 
increased activity of the alternative complement pathway in our models. In this pathway, C3 is cleaved by a com-
plex of C3b with Bb serine protease (C3bBb convertase)26. In an auto amplification loop, C3b generated by this 
complex, binds to a proenzyme complement factor B leading to its cleavage by factor D and generation of more 
C3bBb. Complement factor H competes with Bb for binding to C3b promoting the decay of the convertase. It also 
serves as a cofactor for complement factor I that cleaves C3b. Erythrocytes express several complement regulators 
and receptors. Specifically, erythrocytes maturing in association with macrophages express several C3b decay 
factors and C3b-specific complement receptor CR1, which expression gradually decreases during maturation62. 
This suggests early erythrocytes are sensitive to complement. In RP-deficient zebrafish, expression of factor B was 
increased while that of factor H was decreased, which may increase 3b deposition on erythrocytes promoting 
their engulfment by macrophages and would decrease a proportion of erythrocytes that are able to mature. In 
addition, we found increased expression of complement factor 6. C6 is a key member of the membrane attack 
complex that induces cell lysis. Although lysis of erythrocytes is not a prominent feature of DBA, it may take place 
at the low level. Our data suggest DBA may join the growing list of diseases with over activated complement.
Both interferons and complement system can promote inflammation. In RP-deficient zebrafish we found 
upregulation of inflammatory cytokines and mediators. We also found decreased expression of inhibin-specific 
subunits in RP-deficient zebrafish and human cells, which suggest a shift to activin in the inhibin-activin balance. 
Upregulation of IFNs inhibits hematopoiesis63. Inflammatory cytokines such as TNF and activin can also suppress 
hematopoiesis64.
In adult fish and in human patients, which have both innate and adaptive immune systems, activation of 
innate immune receptors may affect T and B cells. For example, upregulation of interferons may activate mac-
rophages and direct T helper cell development to the pro-inflammatory Th1 pathway65. Increased proportion 
of cytotoxic T cells (decreased T4/T8 ratio) was reported in DBA and may also be connected to interferon 
Figure 6. Inhibitors of TLR3, activin, and complement partially rescued Rps19-deficient zebrafish embryos. 
(A) TLR3 inhibitor decreased expression of interferon mediators irf7 and stat1b, decreased expression of 
inflammatory markers il6 and ptgs2/cox2 and acute phase response gene fos. It also downregulated p21 
responsible for cell cycle arrest and pro-apoptotic inflammatory gene bax, 40 hpf, RT-qPCR. Bars represent the 
mean of three replicates ± sd. Asterisk indicates significant difference in comparison to controls, p < 0.05. (B) 
TLR3 inhibitor improved hematopoiesis in Rps19 morphants, day 3, o-dianizidine staining. 50 embryos per 
group, representative staining is shown. (C) Embryos were injected with rps19 morpholino, MO group was 
left untreated, other groups were treated with TLR3 inhibitor (TLRinh), SB431542 activin inhibitor (SB43) or 
SB290157 complement inhibitor (SB29). Treatments decreased morphological defects and improved survival 
in Rps19-deficient zebrafish embryos. Embryos classified as abnormal had strong defects such as tail kinks, 
curved body, strongly shortened body, arrest at early developmental stage, and underdeveloped eyes. Embryos 
with mild defects had smaller size, smaller eyes and heads. 24 hpf. The experiment was performed in triplicates, 
60 embryos per group; bars represent the mean of three replicates. Number of dead/abnormal/mild/normal 
embryos for MO 10 ± 0.6/15 ± 0.6/30 ± 1.2/5 ± 1; for TLR3 inhibitor 2 ± 1/6 ± 1/37 ± 1/15 ± 0.6; for SB431542 
inhibitor 0 ± 0/4 ± 1/38 ± 2.5/18 ± 1.5; for SB2990157 3 ± 1/7 ± 0.5/35 ± 1.2/15 ± 0.7.
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activation15. Interferons may contribute to the apoptosis of hematopoietic progenitors induced by cytotoxic T 
cells in acquired aplastic anemia66.
Conflicting results associated with studies of immunity in DBA may be explained by differences in status of 
the analyzed patients. Many patients are on corticosteroid therapy, which suppresses inflammation. In patients 
not treated by corticosteroids, autonomous immune response may vary depending if they are in an acute phase or 
in remission, which would be associated with variation in p53 activity. P53 suppresses NFkB and NFkB-mediated 
inflammation67. P53 however promotes interferon responses51.
Our data suggest that the right balance between p53 and immunity is necessary to promote cell health. 
Glucocorticoids used in DBA treatment may work in part by suppressing inappropriate immune activation. 
Inhibitor of TLR3 receptor, inhibitor of activin receptor, and complement inhibitor also improved the condi-
tion of RP-deficient embryos. There are other examples of application of these inhibitors. Blockade of TLR3 was 
recently shown to protect mice from lethal radiation induced syndrome68. Cytokine inhibition has been success-
fully used to treat some rheumatic and autoimmune diseases69 and antibodies targeting interferons and inter-
leukins are being investigated for SLE. Sotatercept that suppresses activin signaling is investigated as a potential 
therapeutic for anemia70. Overall our data suggest that innate immune pathways may contribute to the pathogen-
esis of DBA. Based on our findings, therapies targeting innate immune response or modulating activin signaling 
should further be explored as potential treatments for DBA.
Materials and Methods
Zebrafish. Zebrafish (Danio rerio) lines used AB, rpl11hi3820bTg 45 and tp53zdf1/zdf1 71. Embryos were obtained by 
natural spawning. UCLA Animal Committee approved the study and all methods were performed in accordance 
with the relevant guidelines and regulations.
Human primary cells and cell lines. EBV-immortalized lymphoid cell line from a DBA patient with an 
RPS19 mutation and a cell line from a normal control were a gift from Hanna Gazda (Harvard University, Boston, 
MA). Both cell lines were grown in RPMI-1640, supplemented with 10% FBS. Human fetal liver tissues were 
obtained from Advanced Bioscience Resources Inc (Alameda, CA). Cells were sorted for CD34+ using MACS cell 
separation (Miltenyi Biotec, Auburn, CA). Sorted cells were grown in x-Vivo15 media (Lonza, Basel, Switzerland) 
containing 10% FBS, 50 ng/mL of FLT-3, TPO, and SCF and 20 ng/mL of IL-3 and IL-6. K562 cells were grown 
in RPMI-1640, supplemented with 10% FBS. Primary CD34+ fetal liver cells and K562 cells were transduced 
with lentivirus containing shRNA against RPS19 or scrambled (SCR) shRNA, sorted for GFP at 72 hours, and 
harvested post-transduction, as indicated in results.
Figure 7. Response of innate immune system to RP-deficiency. Tlr3 and Tlr9 receptors are expressed in 
endosomes and can be activated by endogenous RNAs and DNAs that comes from apoptotic cells and 
autophagosomes. In addition, cytoplasmic sensor of dsRNAs Mda5 (encoded by ifih1) was upregulated in 
RP-deficient zebrafish. During DNA damage repair DNA fragments can escape into cytoplasm and converted 
by RNA Pol III into RNAs that may contain dsRNA regions. Once activated, receptors induce expression of 
interferons and pro-inflammatory cytokines, which are released and act on hematopoietic cells. Several factors 
may synergize in decreasing proliferation of hematopoietic cells and shortening their life span.
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Microarray. K562 cells were transduced with lentivirus carrying shRNA against RPS19 or control scram-
bled shRNA and sorted for the GFP marker. RNA was purified with Trizol and analyzed by microarray on an 
Affymetryx platform. The microarray and data analysis were performed at the UCLA DNA Microarray Core. 
Preparation of microarray of Rpl11 mutant has been reported previously12.
RT-qPCR. RNA was prepared using Trizol (Invitrogen, Carlsbad, CA) from 30–40 embryos or from 1–5 mil-
lion cells; 2 μg was used for RT with the random hexamer primers. PCR was performed in triplicates using iQ 
SYBR Green Super Mix. Primers are shown in a Supplemental Table 1. Levels of mRNA were normalized to 
beta-actin and calculated by Cτ method.
Morpholinos. 3 ng of the following morpholinos were injected at the one cell stage: Rps19–specific mor-
pholino targeting exon 3 splicing site 5′- gcttccccgacctttcaaaagacaa and 5 bases mismatch: 5′- gattcctcgaactctcaat-
agacaa (Gene Tools, Philomath, OR).
Staining of erythroid cells. 6 mg of o-dianizidine was dissolved in 50 μl of acetic acid, diluted to 6 ml by 
water, and neutralized by 10 μl of 10 M NaOH following by 4 ml of ethanol and 130 μl of 50% H2O2. Embryos were 
placed in this solution and color development was monitored under a microscope. Embryos were washed with 
water before imaging.
Drug treatments. 100 mM stocks of TLR3 receptor inhibitor (Calbiochem), compound SB431542 (Tocris 
Bioscience, Minneapolis, MN), and compound SB290157 (Santa Cruz Biotechnology, CA) were prepared in 
DMSO and added to fish water to 3 μM concentrations.
Statistics. Each experiment was repeated at least twice, and results of a representative experiment are shown. 
Data are presented as the means of at least tree measurements plus/minus SD. Student’s t test was used for com-
parisons of a variable between two groups.
Data availability. Microarray of Rpl11 mutant data are available at the depository ArrayExpress, Acc: 
E-MEXP-2381.
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